These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cell Culture System for Analysis of Genetic Heterogeneity Within Hepatocellular Carcinomas and Response to Pharmacologic Agents. Gao Q; Wang ZC; Duan M; Lin YH; Zhou XY; Worthley DL; Wang XY; Niu G; Xia Y; Deng M; Liu LZ; Shi JY; Yang LX; Zhang S; Ding ZB; Zhou J; Liang CM; Cao Y; Xiong L; Xi R; Shi YY; Fan J Gastroenterology; 2017 Jan; 152(1):232-242.e4. PubMed ID: 27639803 [TBL] [Abstract][Full Text] [Related]
3. Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Ahn SM; Jang SJ; Shim JH; Kim D; Hong SM; Sung CO; Baek D; Haq F; Ansari AA; Lee SY; Chun SM; Choi S; Choi HJ; Kim J; Kim S; Hwang S; Lee YJ; Lee JE; Jung WR; Jang HY; Yang E; Sung WK; Lee NP; Mao M; Lee C; Zucman-Rossi J; Yu E; Lee HC; Kong G Hepatology; 2014 Dec; 60(6):1972-82. PubMed ID: 24798001 [TBL] [Abstract][Full Text] [Related]
4. The apoptotic effect and associated signalling of HSP90 inhibitor 17-DMAG in hepatocellular carcinoma cells. Leng AM; Liu T; Yang J; Cui JF; Li XH; Zhu YN; Xiong T; Zhang G; Chen Y Cell Biol Int; 2012 Oct; 36(10):893-9. PubMed ID: 22694478 [TBL] [Abstract][Full Text] [Related]
5. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features. Kawai-Kitahata F; Asahina Y; Tanaka S; Kakinuma S; Murakawa M; Nitta S; Watanabe T; Otani S; Taniguchi M; Goto F; Nagata H; Kaneko S; Tasaka-Fujita M; Nishimura-Sakurai Y; Azuma S; Itsui Y; Nakagawa M; Tanabe M; Takano S; Fukasawa M; Sakamoto M; Maekawa S; Enomoto N; Watanabe M J Gastroenterol; 2016 May; 51(5):473-86. PubMed ID: 26553052 [TBL] [Abstract][Full Text] [Related]
7. Exome Sequencing of Oral Squamous Cell Carcinoma Reveals Molecular Subgroups and Novel Therapeutic Opportunities. Su SC; Lin CW; Liu YF; Fan WL; Chen MK; Yu CP; Yang WE; Su CW; Chuang CY; Li WH; Chung WH; Yang SF Theranostics; 2017; 7(5):1088-1099. PubMed ID: 28435450 [TBL] [Abstract][Full Text] [Related]
8. TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma. Ki Kim S; Ueda Y; Hatano E; Kakiuchi N; Takeda H; Goto T; Shimizu T; Yoshida K; Ikura Y; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Uemoto S; Chiba T; Ogawa S; Marusawa H Int J Cancer; 2016 Dec; 139(11):2512-8. PubMed ID: 27511114 [TBL] [Abstract][Full Text] [Related]
9. In-silico drug screening and potential target identification for hepatocellular carcinoma using Support Vector Machines based on drug screening result. Yang WL; Lee YE; Chen MH; Chao KM; Huang CY Gene; 2013 Apr; 518(1):201-8. PubMed ID: 23220021 [TBL] [Abstract][Full Text] [Related]
10. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections. Tornesello ML; Buonaguro L; Tatangelo F; Botti G; Izzo F; Buonaguro FM Genomics; 2013 Aug; 102(2):74-83. PubMed ID: 23583669 [TBL] [Abstract][Full Text] [Related]
12. Hepatic aflatoxin B1-DNA adducts and TP53 mutations in patients with hepatocellular carcinoma despite low exposure to aflatoxin B1 in southern Japan. Shirabe K; Toshima T; Taketomi A; Taguchi K; Yoshizumi T; Uchiyama H; Harimoto N; Kajiyama K; Egashira A; Maehara Y Liver Int; 2011 Oct; 31(9):1366-72. PubMed ID: 21745313 [TBL] [Abstract][Full Text] [Related]
13. Genomic landscape of lymphoepithelioma-like hepatocellular carcinoma. Chan AW; Zhang Z; Chong CC; Tin EK; Chow C; Wong N J Pathol; 2019 Oct; 249(2):166-172. PubMed ID: 31168847 [TBL] [Abstract][Full Text] [Related]
14. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma. Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368 [TBL] [Abstract][Full Text] [Related]
15. Translating the molecular diversity of hepatocellular carcinoma into clinical practice. Schulze K; Zucman-Rossi J Mol Cell Oncol; 2016 Jul; 3(4):e1057316. PubMed ID: 27652310 [TBL] [Abstract][Full Text] [Related]
16. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Boyault S; Rickman DS; de Reyniès A; Balabaud C; Rebouissou S; Jeannot E; Hérault A; Saric J; Belghiti J; Franco D; Bioulac-Sage P; Laurent-Puig P; Zucman-Rossi J Hepatology; 2007 Jan; 45(1):42-52. PubMed ID: 17187432 [TBL] [Abstract][Full Text] [Related]
17. Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias. Zondervan PE; Wink J; Alers JC; IJzermans JN; Schalm SW; de Man RA; van Dekken H J Pathol; 2000 Oct; 192(2):207-15. PubMed ID: 11004697 [TBL] [Abstract][Full Text] [Related]
18. The genomic landscape of hepatoblastoma and their progenies with HCC-like features. Eichenmüller M; Trippel F; Kreuder M; Beck A; Schwarzmayr T; Häberle B; Cairo S; Leuschner I; von Schweinitz D; Strom TM; Kappler R J Hepatol; 2014 Dec; 61(6):1312-20. PubMed ID: 25135868 [TBL] [Abstract][Full Text] [Related]
19. Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma. Pezzuto F; Izzo F; Buonaguro L; Annunziata C; Tatangelo F; Botti G; Buonaguro FM; Tornesello ML Oncotarget; 2016 Aug; 7(34):54253-54262. PubMed ID: 27276713 [TBL] [Abstract][Full Text] [Related]
20. Profiling of exome mutations associated with progression of HBV-related hepatocellular carcinoma. Woo HG; Kim SS; Cho H; Kwon SM; Cho HJ; Ahn SJ; Park ES; Lee JS; Cho SW; Cheong JY PLoS One; 2014; 9(12):e115152. PubMed ID: 25521761 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]